Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

ABUS

Arbutus Biopharma Corp

Last Close
Jun 13 • 02:52PM ET
3.17
Dollar change
-0.08
Percentage change
-2.31 		%
Held by: IWM VTI VXF IBB IWO IWN VTWO ITOT IWC FESM Scroll to Statements
IndexRUT P/E- EPS (ttm)-0.44 Insider Own23.35% Shs Outstand169.87M Perf Week-4.94%
Market Cap599.19M Forward P/E- EPS next Y-0.39 Insider Trans-0.08% Shs Float144.66M Perf Month11.01%
Income-74.39M PEG- EPS next Q-0.10 Inst Own49.97% Short Float3.47% Perf Quarter21.65%
Sales12.99M P/S46.13 EPS this Y11.36% Inst Trans4.32% Short Ratio4.01 Perf Half Y54.88%
Book/sh0.64 P/B4.99 EPS next Y-0.51% ROA-43.56% Short Interest5.03M Perf Year27.00%
Cash/sh0.68 P/C4.64 EPS next 5Y- ROE-57.54% 52W Range1.69 - 3.64 Perf YTD27.00%
Dividend Est.- P/FCF- EPS past 5Y18.41% ROI-60.86% 52W High-12.77% Beta1.97
Dividend TTM- Quick Ratio6.69 Sales past 5Y55.33% Gross Margin89.03% 52W Low87.87% ATR (14)0.14
Dividend Ex-Date- Current Ratio6.69 EPS Y/Y TTM3.41% Oper. Margin-616.64% RSI (14)50.47 Volatility5.23% 4.52%
Employees73 Debt/Eq0.07 Sales Y/Y TTM-60.80% Profit Margin-572.81% Recom1.40 Target Price4.40
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-0.69% Payout- Rel Volume0.46 Prev Close3.25
Sales Surprise-43.56% EPS Surprise9.09% Sales Q/Q-77.09% EarningsMay 02 BMO Avg Volume1.25M Price3.17
SMA20-2.05% SMA505.67% SMA20030.85% Trades Volume482,017 Change-2.31%
Date Action Analyst Rating Change Price Target Change
Feb-02-22Upgrade Jefferies Hold → Buy $5
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Show Previous Ratings
Jun-06-24 11:15AM
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
(GlobeNewswire) -7.99%
11:15AM
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
(GlobeNewswire)
Jun-05-24 02:30AM
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
(GlobeNewswire) +8.68%
May-29-24 07:30AM
Arbutus to Participate in Jefferies Global Healthcare Conference
(GlobeNewswire)
May-22-24 02:00AM
Arbutus to Present Imdusiran Data at EASL Congress 2024
(GlobeNewswire) +6.23%
12:03PM Loading…
May-17-24 12:03PM
Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
(MT Newswires)
10:40AM
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
(MT Newswires)
09:00AM
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
(Business Wire)
May-07-24 07:30AM
Arbutus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
May-03-24 11:19AM
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
(Insider Monkey)
03:24AM
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
(GuruFocus.com)
May-02-24 12:55PM
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
(InvestorPlace)
08:58AM
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
(GuruFocus.com)
08:45AM
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
07:44AM
Arbutus: Q1 Earnings Snapshot
(Associated Press Finance)
07:30AM Loading…
07:30AM
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
(GlobeNewswire)
07:25AM
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
(GlobeNewswire)
Apr-30-24 09:40AM
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
(Zacks)
Apr-18-24 07:30AM
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
(GlobeNewswire)
Apr-04-24 08:30AM
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
(GlobeNewswire)
Mar-08-24 07:30AM
Arbutus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Mar-01-24 08:17AM
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Feb-29-24 11:14PM
Q4 2023 Arbutus Biopharma Corp Earnings Call
(Thomson Reuters StreetEvents)
08:40AM
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
07:52AM
Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials
(GuruFocus.com)
07:30AM
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
Feb-15-24 07:30AM
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
(GlobeNewswire)
Jan-08-24 07:30AM
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
(GlobeNewswire)
Nov-09-23 04:24PM
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
(GlobeNewswire)
04:01PM
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting
(GlobeNewswire)
09:12AM Loading…
09:12AM
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-08-23 07:30AM
Arbutus to Present at Jefferies London Healthcare Conference
(GlobeNewswire)
01:16AM
Q3 2023 Arbutus Biopharma Corp Earnings Call
(Thomson Reuters StreetEvents)
Nov-07-23 08:05AM
Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results
(GuruFocus.com)
07:40AM
Arbutus: Q3 Earnings Snapshot
(Associated Press Finance)
07:30AM
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
07:15AM
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
(GlobeNewswire)
Oct-30-23 09:32AM
12 Best Micro Cap Stocks To Invest In
(Insider Monkey)
Oct-24-23 07:30AM
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
(GlobeNewswire)
Oct-18-23 07:30AM
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
(GlobeNewswire) -5.82%
Oct-11-23 08:05AM
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023
(GlobeNewswire)
Sep-12-23 10:56AM
Arbutus BioPharma narrows research focus to extend cash runway
(American City Business Journals) -7.73%
08:58AM
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
(Zacks)
Sep-11-23 04:15PM
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
(GlobeNewswire)
Sep-07-23 07:30AM
Arbutus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Aug-04-23 03:29PM
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-03-23 08:55AM
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
(Zacks)
07:49AM
Arbutus: Q2 Earnings Snapshot
(Associated Press Finance)
07:30AM
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
(GlobeNewswire)
Jul-23-23 10:19AM
Arbutus Biopharma Corporation (NASDAQ:ABUS) has caught the attention of institutional investors who hold a sizeable 38% stake
(Simply Wall St.)
Jul-20-23 07:30AM
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
(GlobeNewswire)
Jul-12-23 07:30AM
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
(GlobeNewswire)
Jul-10-23 04:01PM
Arbutus Appoints Two New Executives
(GlobeNewswire)
Jun-23-23 09:40AM
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
(Zacks)
Jun-21-23 07:30AM
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
(GlobeNewswire)
02:01AM
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
(GlobeNewswire)
Jun-07-23 09:40AM
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
(Zacks)
02:01AM
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
(GlobeNewswire)
Jun-01-23 11:29AM
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
(Zacks)
May-31-23 07:30AM
Arbutus to Present at Jefferies Healthcare Conference
(GlobeNewswire)
May-30-23 09:26AM
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
(Zacks)
May-29-23 10:08AM
FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
(Zacks)
May-22-23 09:40AM
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
(Zacks)
May-17-23 07:38AM
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
(Simply Wall St.)
May-09-23 12:00PM
Arbutus (ABUS) Upgraded to Buy: Here's Why
(Zacks)
07:30AM
Arbutus to Present at JMP Securities Life Sciences Conference
(GlobeNewswire)
May-04-23 11:52PM
Q1 2023 Arbutus Biopharma Corp Earnings Call
(Thomson Reuters StreetEvents)
09:40AM
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
(Zacks)
08:55AM
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
07:30AM
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
(GlobeNewswire)
Apr-27-23 03:20AM
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
(GlobeNewswire)
Apr-25-23 11:57AM
Why Arbutus Biopharma Stock Is Plunging Today
(Benzinga) -12.46%
11:50AM
Why Arbutus Biopharma Stock Is Sinking Today
(Motley Fool)
07:30AM
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
(GlobeNewswire)
Apr-20-23 07:30AM
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
(GlobeNewswire)
Apr-18-23 04:01PM
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
(GlobeNewswire)
02:18PM
Arbutus Biopharma Corporation's (NASDAQ:ABUS) Share Price Could Signal Some Risk
(Simply Wall St.)
Apr-12-23 12:37PM
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
(Benzinga)
Apr-11-23 03:30PM
UPDATE 1-Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight
(Reuters)
01:00PM
Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight
(Reuters)
Apr-04-23 04:08PM
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
(Benzinga)
08:22AM
UPDATE 2-Arbutus files patent infringement lawsuit against Pfizer/BioNTech over COVID shots
(Reuters)
08:17AM
Arbutus files patent lawsuit against Pfizer/BioNTech over COVID vaccines
(Reuters)
07:52AM
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
(GlobeNewswire)
Mar-24-23 12:29PM
Lab Notes: Arbutus begins human testing of potential hepatitis B cure
(American City Business Journals)
Mar-19-23 10:17AM
Those who invested in Arbutus Biopharma (NASDAQ:ABUS) three years ago are up 108%
(Simply Wall St.)
Mar-16-23 07:30AM
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
(GlobeNewswire)
Mar-14-23 04:05PM
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
(GlobeNewswire)
Mar-10-23 06:36PM
Moderna loses bid to shift liability in COVID-19 vaccine patent case
(Reuters)
Mar-06-23 01:55AM
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-03-23 03:50AM
Q4 2022 Arbutus Biopharma Corp Earnings Call
(Thomson Reuters StreetEvents)
Mar-02-23 09:25AM
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
07:30AM
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
(GlobeNewswire)
Feb-16-23 07:30AM
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
(GlobeNewswire)
Feb-15-23 12:02PM
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
(Reuters)
Feb-13-23 07:01AM
Arbutus Biopharma Corporation's (NASDAQ:ABUS) top owners are individual investors with 42% stake, while 31% is held by institutions
(Simply Wall St.)
Feb-06-23 07:30AM
Arbutus to Participate in Three Upcoming Investor Conferences
(GlobeNewswire)
Jan-27-23 07:30AM
Arbutus Announces Resignation of Board Member
(GlobeNewswire)
Jan-11-23 10:24PM
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?
(Zacks)
Jan-05-23 07:30AM
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
(GlobeNewswire)
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McElhaugh Michael J.Interim President & CEOFeb 02 '24Sale2.3110,16423,5041,504,793Feb 05 07:54 PM
Sofia Michael J.Chief Scientific OfficerFeb 02 '24Sale2.319,98223,0831,485,121Feb 05 07:54 PM
HASTINGS DAVID CChief Financial OfficerFeb 02 '24Sale2.319,59322,184181,907Feb 05 07:54 PM
Sims KarenChief Medical OfficerFeb 02 '24Sale2.314,35810,078125,542Feb 05 07:55 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.